

Reference Data

Financial results for the year ended March 31, 2020



Billions of yen	FY2017/3	FY2018/3	FY2019/3			FY2020/3		
	Full year	Full year	1H	2H	Full year	1H	2H	Full year
Revenue	749.2	717.0	335.7	372.9	708.6	291.0	300.0	591.0
Operating Profit	0.7	56.2	30.6	52.0	82.6	17.5	-10.8	6.7
% vs Revenue	0.1%	7.8%	9.1%	13.9%	11.7%	6.0%	-3.6%	1.1%
Profit before income taxes	3.0	56.2	33.8	54.1	87.9	20.1	-8.3	11.8
% vs Revenue	0.4%	7.8%	10.1%	14.5%	12.4%	6.9%	-2.8%	2.0%
Profit attributable to owners of the parent	3.9	34.7	22.8	43.7	66.5	16.3	-8.7	7.6
% vs Revenue	0.5%	4.8%	6.8%	11.7%	9.4%	5.6%	-2.9%	1.3%
EPS	¥10.01	¥87.76	¥167.86			¥19.93		
Annual Dividends	¥16	¥36	¥60			¥40		
ROE	0.7%	6.3%	11.2%			1.3%		
FCF	56.6	90.2	43.5			-4.8		
Exchange Rate :								
US \$	¥108	¥111	¥110	¥112	¥111	¥109	¥109	¥109
EURO	¥119	¥130	¥130	¥127	¥128	¥121	¥120	¥121

Note: From FY2019/3, a part of sales promotion expenses is deducted from revenue, which had been booked as SG&A previously. FY2019/3 Revenue is an amount after deducting ¥8.3B.

Financial Highlights for the year ended March 31, 2020: by Segments




Billions of yen		FY2017/3	FY2018/3	FY2019/3			FY2020/3		
		Full year	Full year	1H	2H	Full year	1H	2H	Full year
Imaging Products Business	Revenue	383.0	360.7	150.9	145.2	296.1	119.0	106.8	225.8
	Operating Profit	17.1	30.2	13.2	8.8	22.0	2.0	-19.1	-17.1
		(28.1)	(36.0)	(13.6)	(9.0)	(22.6)	(2.2)	(-16.6)	(-14.4)
Precision Equipment Business	Revenue	248.0	226.3	121.6	152.9	274.5	115.1	124.6	239.7
	Operating Profit	13.4	53.3	29.8	51.9	81.7	25.4	21.3	46.7
		(48.1)	(53.3)	(29.8)	(51.9)	(81.7)	(25.4)	(21.3)	(46.7)
Healthcare Business	Revenue	55.7	56.8	29.4	36.0	65.4	30.0	32.0	62.0
	Operating Profit	-0.6	-3.2	-2.3	0.4	-1.9	-1.2	-1.2	-2.4
		(-0.1)	(-3.2)	(-2.3)	(0.4)	(-1.9)	(-1.2)	(-1.2)	(-2.4)
Industrial Metrology and Others	Revenue	62.4	73.2	33.7	38.8	72.5	26.7	36.6	63.3
	Operating Profit	3.7	5.0	2.7	4.2	6.9	2.4	0.7	3.1
		(5.5)	(7.8)	(3.5)	(4.0)	(7.5)	(2.4)	(0.7)	(3.1)
Corporate P/L non-attributable to any reportable segments	Revenue	—	—	—	—	—	—	—	—
	Operating Profit	-32.8	-29.1	-12.8	-13.3	-26.1	-11.1	-12.5	-23.6
		(-27.5)	(-29.1)	(-12.8)	(-12.8)	(-25.6)	(-9.4)	(-12.5)	(-21.9)
Consolidated	Revenue	749.2	717.0	335.7	372.9	708.6	291.0	300.0	591.0
	Operating Profit	0.7	56.2	30.6	52.0	82.6	17.5	10.8	6.7
		(54.1)	(64.9)	(31.8)	(52.6)	(84.4)	(19.4)	(-8.2)	(11.2)

Note: From FY2019/3, a part of sales promotion expenses is deducted from revenue, which had been booked as SG&A previously. FY2019/3 Revenue is an amount after deducting ¥8.3B. Figures in parentheses are the operating profit excluding the restructuring relevant expenses.


Financial Position Breakdown



ASSETS



LIABILITIES/ EQUITY



Note: A breakdown of interest-bearing debt as of March 31, 2020 is ¥29.9B in bonds and ¥109.2B in other borrowings.


(Leases Liabilities at the beginning of FY2020/3 has increased approx. ¥17.0B upon the adoption of IFRS 16.)

Equity ratio is ratio of equity attributable to owners of the parent to total assets. Cash and Cash Equivalents excludes time deposits with maturities of three months or more.


Capital Expenditures, Depreciation and Inventory



CAPITAL EXPENDITURES, DEPRECIATION



INVENTORY BREAKDOWN



Note: In FY2020/3, "CAPITAL EXPENDITURES" includes the leased assets of approx. ¥3.0B upon the adoption of IFRS16.


"DEPRECIATION" includes the amortization of capitalized R&D costs from the FY2018/3 and depreciation of the leased asset of approx. ¥4.0B in FY2020/3, as mentioned above.

Revenue Breakdown




BY SEGMENT

Billions of yen




BY REGION

Billions of yen




Note: The outside and inside circles show the breakdown of F2020/3 revenue of ¥591.0B and FY2019/3 revenue of ¥708.6B, respectively.

R&D EXPENDITURES




R&D EXPENDITURES BREAKDOWN




Note: R&D expenditures after FY2018/3 includes capitalization of some development expenditures.

Cash Flow History



Note: FCF (free cash flows) = CF from operating activities + CF from investing activities; Japanese Standard is employed for FY2015/3 and prior, and IFRS is adopted for FY2016/3 and after.
 FCF + CF from financial activities + Effect of exchange rate changes on cash and cash equivalents = net increase (decrease) in cash and cash equivalents


Imaging Products Business: Sales Units




Precision Equipment Business Sales Units




FPD LITHOGRAPHY SYSTEMS SALES BY GENERATION




SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES BY TECHNOLOGY (INCL. REFURBISHED)



Note: The unit sales of new semiconductor lithography systems is 17 units in FY2018/3, 21 units in FY2019/3 and 34 units (forecast) in FY2020/3.



Precision Equipment Business: Sales Units



Disclaimer Regarding Forecast and Projections



Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.

